I am a medical oncologist at the University of Michigan Medicine School and Section Head for Breast Oncology in the Division of Hematology/Oncology, Breast Oncology Disease Lead and Co-Chair of the Breast Clinical Research Team in the Cancer Center, and Associate Division Chief of Clinical Research. I also serve as the Co-Chair of the SWOG Symptom Management and Quality of Life Committee, and a member of the NIH Symptom Management and Quality of Life Steering Committee. My academic research career is focused on translational research in breast oncology, and my primary interest is in predictors of toxicity of therapy, including investigation of mechanisms underlying development of endocrine therapy toxicity and evaluation of patient-reported outcomes. I have substantial experience conducting clinical trials, including serving as Study Chair of S1202, a phase III SWOG randomized trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias, and am quality of life co-chair for a number of ongoing clinical trials, including NSABP GI-004 and SWOG S1418. In addition to these clinical trials, I have also conducted multiple translational studies involving analyses of clinical, biochemical, and genetic predictors of toxicity of adjuvant endocrine therapy for breast cancer. I currently have funding from the V Foundation to examine inflammatory lipid mediators in the development of aromatase inhibitor-associated musculoskeletal symptoms. Previously, I had funding from a NCI K award, a Damon Runyon Clinical Investigator Award, and an American Cancer Society Research Scholar Grant, all of which were related to identifying predictors of endocrine therapy toxicity. I have previously co-authored 90 peer-reviewed and an additional 46 non-peer-reviewed manuscripts related to breast cancer and symptom management, many of which involve precision medicine.